Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Current molecular diagnostics in cancer patients is based on needle biopsies, which,
however, face serious limitations which can lead to false decisions. Individual tumors consist …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

New sensitive assays are currently available for the detection of circulating tumor DNA
(ctDNA) and circulating tumor cells (CTC). However, there remains a need for …

The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

Liquid biopsy is based on minimally invasive blood tests and has a high potential to
significantly change the therapeutic strategy in cancer patients, providing an extremely …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Recent technological advances have enabled the detection and detailed characterization of
circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) in blood samples from …